Destiny Pharma PLC's (LON:DEST) Neil Clark and Shaun Claydon talk to Proactive London about their results for the year which ended 31 December 2020.
The company is about to start Phase 3 preparation following the recent positive Phase 2b clinical trial results for the XF-73 nasal gel to prevent post-surgical infections.
Key highlights during the period include, buying NTCD-M3, a candidate for the a candidate for the prevention of C. difficile infection recurrence to start next year.